Immatics Biotechnologies GmbH - Company Profile
Powered by 
All the sales intelligence you need on Immatics Biotechnologies GmbH in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Immatics Biotechnologies GmbH fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Immatics Biotechnologies GmbH.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Immatics Biotechnologies GmbH Clinical Trials
Determine Immatics Biotechnologies GmbH go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.
A sample of Immatics Biotechnologies GmbH Clinical Trials data
| Trial Title | Trial Identifier | Drug Name | Therapy Area | Indication | Trial Phase | Trial Status | Sponsor |
|---|---|---|---|---|---|---|---|
| Deserunt mollit sunt Lorem | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Pfizer Inc |
| Extension Study to Evaluate Long-term-safety of IMA901 Plus GM-CSF in Advanced Renal Cell Carcinoma Patients who Achieved a Decrease in Tumor Load or Stabilization of Their Disease after Participation in the Open-label, Multicenter IMA901-202 Phase II Study | GDCT0144753 | IMA-901 | Oncology | Kidney Cancer (Renal Cell Cancer); Renal Cell Carcinoma | Phase II | Completed | Immatics Biotechnologies GmbH |
| IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101) (IMA910-101) | GDCT0015867 | IMA-910 | Oncology | Carcinomas; Colorectal Cancer; Metastatic Colorectal Cancer | Phase I/II | Completed | Immatics Biotechnologies GmbH |
| IMA901 in Advanced Renal Cell Carcinoma Patients with Measurable Disease (IMA901-202) | GDCT0013401 | IMA-901 | Oncology | Renal Cell Carcinoma | Phase II | Completed | Immatics Biotechnologies GmbH |
Feature
GlobalData’s Clinical Trials database (CTDB) is a highly comprehensive source of Clinical Trials.
The database covers planned, ongoing, completed and terminated/suspended/withdrawn clinical trials.
Clinical Trials database provides intelligence on global clinical trials for all indications. The data is sourced from:
- 250+ clinical trial registries
- 200+ scientific and investor conferences, company pipelines, press releases, and SEC filings.
Benefit
The Clinical Trials database collects information on various parameters to provide a Clinical Trial overview as well as Clinical Trial details, Drug details, Patient details, Trial Results, Location(s)/Sponsor(s) and Contact Detail(s).
Access:
- Detailed trial information.
- Drug information.
- Patient information, including inclusion and exclusion criteria.
- Trial results, as reported in the public domain.
- Biomarkers used for patient stratification/selection & outcome measures.
- Enrolment parameters.
- Investigators involved in clinical trials.
- Trials sites and locations.
- Contact information.
Value
Competitive Activity – keep an eye on planned or ongoing trials, as well as the trials currently recruiting and who is sponsoring them.
Geographic Analysis - see where trials are being run.
Trend Analysis - view top sponsors, indications, phase, status and more with Trial Analytics.
Find information on trials contacts, as well as Site and Investigator information.
Get information on trial successes and failures.
Get intelligence on CROs engaged in clinical trials.
Use as a business development tool for CROs.
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer